Heidelberg Pharma AG Stock price

Equities

HPHA

DE000A11QVV0

Biotechnology & Medical Research

Delayed Xetra 12:36:27 2024-03-28 pm EDT 5-day change 1st Jan Change
3.12 EUR +1.63% Intraday chart for Heidelberg Pharma AG +1.30% -16.58%
Sales 2024 * 11.5M 12.39M Sales 2025 * 15M 16.16M Capitalization 145M 157M
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 12.6 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 9.69 x
P/E ratio 2024 *
-10.4 x
P/E ratio 2025 *
-24 x
Employees 101
Yield 2024 *
-
Yield 2025 *
-
Free-Float 16.94%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.63%
1 week+1.30%
Current month+1.96%
1 month+2.30%
3 months-14.75%
6 months-8.50%
Current year-16.58%
More quotes
1 week
3.02
Extreme 3.02
3.25
1 month
2.87
Extreme 2.87
3.60
Current year
2.87
Extreme 2.87
3.73
1 year
2.63
Extreme 2.63
4.65
3 years
2.63
Extreme 2.63
8.68
5 years
2.00
Extreme 2
9.70
10 years
1.39
Extreme 1.3866
9.70
More quotes
Managers TitleAgeSince
Chief Executive Officer - 11-12-31
Director of Finance/CFO - 23-04-30
Chief Tech/Sci/R&D Officer - 21-02-28
Members of the board TitleAgeSince
Director/Board Member 60 05-04-28
Director/Board Member 74 00-12-13
Director/Board Member 57 12-05-24
More insiders
Date Price Change Volume
24-03-28 3.12 +1.63% 11,623
24-03-27 3.07 +0.66% 16,717
24-03-26 3.05 -1.61% 5,980
24-03-25 3.1 +0.32% 31,880
24-03-22 3.09 +0.32% 19,122

Delayed Quote Xetra, March 28, 2024 at 12:36 pm EDT

More quotes
Heidelberg Pharma AG, formerly Wilex AG, is a Germany-based Company, which is engaged in the biopharmaceuticals sector. The Company focuses on the research and development of therapy treatments for oncology area. It aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Company’s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. It also offers preclinical contract research services.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.12 EUR
Average target price
11.3 EUR
Spread / Average Target
+262.18%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Heidelberg Pharma AG - Xetra